22nd Century Group (XXII:NYSE) Investor Relations Material

Overview

22nd Century Group, Inc.: Pioneering Tobacco Harm Reduction and Enhancing Health and Wellness through Plant Science Agricultural biotech company, 22nd Century Group, Inc., is making waves with its groundbreaking technology aimed at reducing nicotine in tobacco products and enhancing health and wellness through plant science. The New York-based company is developing very low nicotine content tobacco and cigarette products under the VLN King and VLN Menthol King names, along with SPECTRUM research cigarettes for use in independent clinical studies. The company has also partnered with Keygene N.V. to develop hemp/cannabis plants that boast exceptional cannabinoid profiles and other superior agronomic traits. These plants have potential applications in the medical, therapeutic, and agricultural industries. Founded in 1998, 22nd Century Group, Inc. is pushing the boundaries of agricultural biotech with its focus on tobacco harm reduction and enhancing health and wellness.

Frequently Asked Questions

What is 22nd Century Group's ticker?

22nd Century Group's ticker is XXII

What exchange is 22nd Century Group traded on?

The company's shares trade on the NYSE stock exchange

Where are 22nd Century Group's headquarters?

They are based in Clarence, New York

How many employees does 22nd Century Group have?

There are 11-50 employees working at 22nd Century Group

What is 22nd Century Group's website?

It is xxiicentury.com

What type of sector is 22nd Century Group?

22nd Century Group is in the Healthcare sector

What type of industry is 22nd Century Group?

22nd Century Group is in the Biotechnology industry

Who are 22nd Century Group's peers and competitors?

The following five companies are 22nd Century Group's industry peers:

- OptiBiotix Health Plc

- Erytech Pharma S.A.

- Acceleron Pharma Inc.

- Open Orphan plc

- Entasis Therapeutics Holdings Inc.